Overview

Oral Anticoagulant Apixaban for Treatment of Venous Thromboembolism

Status:
Recruiting
Trial end date:
2022-05-31
Target enrollment:
Participant gender:
Summary
Patients who have developed a venous thrombosis will receive apixaban to treat and prevent a secondary thromboembolism.
Phase:
Phase 2
Details
Lead Sponsor:
New York Medical College
Treatments:
Anticoagulants
Apixaban